Asia PR News

SYDNEY, Oct. 31 /MediaNet International-AsiaNet/ –

Ventracor Limited (ASX: VCR) today announced a senior management
appointment to further accelerate its global clinical trials and regulatory
approval timelines in US and European markets.

Ventracor Chief Executive Officer, Colin Sutton PhD said: "We have
appointed Tom Richards PhD as Vice President, Clinical and Regulatory Affairs
as enrolment in our CE Mark Trial and US feasibility study approach completion
in the first quarter of 2006."

"Tom has successfully shepherded numerous medical device products through
the European and US FDA regulatory process.

"He has an impressive array of experience in clinical and regulatory
affairs gained at Teraklin AG (a multinational liver dialysis company), Karl
Storz Endoscopy, Pharmacia Ophthalmics, and Staar Surgical," Dr Sutton said.

Tom is the inventor of seven issued US patents, and has served as an
advisor to several venture capital organisations and development stage
companies.

He will be based in the US and report to Chief Operating Officer Peter
Crosby.

About Ventracor
Ventracor is a global medical device company that has developed a blood
pump, the VentrAssist™ left ventricular assist system (LVAS) for patients in
cardiac failure. The company hopes to bring the VentrAssist™ to the global
market in record time, and expects to obtain a significant share of the huge
potential market.

For further information, please contact:
Andrew Geddes Peter Crosby
Manager, Investor Relations Chief Operating Officer
Ventracor Limited Ventracor Inc
+ 6 1 2 9406 3086 +1 303 570-3327

Source: Ventracor Limited